![]() |
市场调查报告书
商品编码
1499443
药物筛检市场:按产品类型、样本类型、最终用户划分 - 2024-2030 年全球预测Drug Screening Market by Product (Consumables, Instruments, Services), Sample Type (Breath Samples, Hair Samples, Oral Fluid Samples), End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年药物筛检市场规模为86.6亿美元,2024年达98.9亿美元,预计2030年将达到222.5亿美元,复合年增长率为14.42%。
药物筛检是测试尿液、血液、头髮或唾液等生物样本以识别是否有非法或处方药物或其代谢物的过程。这个过程通常用于各种环境,包括就业、刑事司法、体育和成瘾治疗,以确保个人遵守毒品政策或不含违禁物质。提高职场的安全性和合规性、全球处方药和非处方药消费量的增加以及强制进行药物测试的更严格的政府法规和组织政策是主要驱动因素。然而,先进测试技术的高成本和药物检测窗口的可变性可能会阻碍采用。然而,更灵敏和快速测试的开拓以及对行动和现场药物测试服务不断增长的需求预计将为市场成长创造潜在机会。
主要市场统计 | |
---|---|
基准年[2023] | 86.6亿美元 |
预测年份 [2024] | 98.9亿美元 |
预测年份 [2030] | 222.5亿美元 |
复合年增长率(%) | 14.42% |
区域洞察
由于职场安全、效率以及公共卫生意识的增强,亚太地区的药物筛检正在显着增长。由于亚太地区国家人口多样化且药物滥用率各异,因此对药物检测服务的需求因地区而异。随着政府机构努力遏制药物滥用,对药物筛检设备和服务的需求不断增长。由于严格的监管要求和职场安全法规的执行,美洲地区是药物筛检的发展中市场之一。阿片类药物危机让药物检测受到更多关注。在美洲,专利註册不断发展,以反映药物检测方法和套件的技术创新。欧盟国家非常重视公共卫生和职场安全,并制定了严格的药物筛检实务法律。资料保护条例也影响职场药物检测管理。在毒品法严格的中东国家,药物筛检市场波动很大,而且往往受到政府政策的强制。非洲的药物筛检市场正在兴起,人们对药物筛检的认识和需求正在不断增加,这主要受到公共卫生宣传活动和国际职场安全标准的影响。欧洲国家在研发方面投入巨资,开发了符合高精度和可靠性标准的先进药物筛检技术。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在药物筛检市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对药物筛检市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在药物筛检市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[199 Pages Report] The Drug Screening Market size was estimated at USD 8.66 billion in 2023 and expected to reach USD 9.89 billion in 2024, at a CAGR 14.42% to reach USD 22.25 billion by 2030.
Drug screening is the process of checking biological samples, such as urine, blood, hair, or saliva, to identify the existence of illegal or prescription drugs or their metabolites. This process is commonly used in various contexts, including employment, criminal justice, sports, and treatment of addiction, ensuring individuals are compliant with drug policies or are free from prohibited substances. Increased safety and compliance in workplaces, increasing consumption of both prescription and non-prescription drugs worldwide, and strict regulations by governments and organizational policies mandating drug testing are significant drivers. However, the high costs of advanced testing technologies and variability in drug detection windows can deter adoption. Nevertheless, the development of more sensitive and faster tests and the growing need for mobile and on-site drug testing services are expected to create potential opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 8.66 billion |
Estimated Year [2024] | USD 9.89 billion |
Forecast Year [2030] | USD 22.25 billion |
CAGR (%) | 14.42% |
Regional Insights
The Asia-Pacific region has seen substantial growth in drug screening due to increasing awareness about the safety and efficiency of workplaces and public health. APAC countries have diverse populations and exhibit varying rates of substance abuse, which influences the need for drug testing services differently across the region. Government agencies have advanced their efforts in curbing drug abuse, translating into a higher need for drug screening devices and services. The Americas region is one of the evolved markets for drug screening due to strict regulatory requirements and the enforcement of workplace safety regulations. The opioid crisis has further heightened the focus on drug testing. The Americas region continues evolving in patent registrations, reflecting ongoing drug testing methodologies and kit innovations. EU countries focus strongly on public health and workplace safety, with rigorous laws governing drug screening practices. The data protection regulation also impacts the administration of workplace drug testing. With stringent anti-drug laws, countries in the Middle East have a variable market for drug screening, often mandated by government policies. Africa's drug screening market is emerging, with an increasing awareness and need for drug screening primarily influenced by public health campaigns and international workplace safety standards. European countries invest significantly in research and development, which has led to advanced drug screening technologies designed to meet high accuracy and reliability standards.
Market Insights
The market dynamics represent an ever-changing landscape of the Drug Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Innovative Partnership Launches Virtual Drug Screening Platform
eMed, a digital health company, partnered with i3Screen, an established provider of drug screening solutions, to introduce virtual drug testing services. This new platform is designed to facilitate remote drug screening, utilizing eMed's patented technology to ensure the integrity and confidentiality of the testing process. The service is tailored for employers and organizations looking to implement drug testing efficiently while minimizing the need for physical interactions. This partnership enhances the accessibility and effectiveness of drug testing programs and aligns with current trends toward more digital and remote healthcare solutions. [Published On: 2024-05-15]
Launch of Accurate Background's Advanced Drug and Health Screening Services
Accurate Background, a provider of background and identity services, has recently expanded its offerings by launching a new, enhanced drug and health screening service. This service is designed to accommodate the growing demand for efficient and comprehensive employee screening processes. With this advancement, the company introduces a streamlined platform integrating enhanced drug testing methods with robust health screening capabilities. Employers benefit from this service as it provides a more efficient way to conduct pre-employment health assessments, enabling faster and more informed hiring decisions. This initiative underscores Accurate Background's commitment to innovating within the industry and enhances its ability to support employers in maintaining a safe and compliant workplace. [Published On: 2024-04-04]
bioXcelerate Revolutionizes Drug Discovery with AI-Powered Screening Tool
bioXcelerate announced the launch of a cutting-edge artificial intelligence (AI) tool designed to expedite the drug discovery process significantly. This innovative technology aims to streamline the early stages of drug development by enhancing the screening of chemical compounds and expediting the identification of promising drug candidates. By leveraging AI, bioXcelerate anticipates reducing the time and costs traditionally associated with these phases, potentially accelerating the timeline for bringing new drugs to market. This breakthrough is instrumental in ushering in a new era of faster, more efficient drug discovery, particularly beneficial in addressing rapidly evolving global health challenges. [Published On: 2024-03-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug Screening Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Drug Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuSourceHR, Inc., ACM Global Laboratories, Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Clinical Reference Laboratory, Inc., Cordant Health Solutions, Danaher Corporation, Dragerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., Intoximeters, Inc., Laboratory Corporation of America Holdings, Lifeloc Technologies, Inc., Merck KGaA, Omega Laboratories, Inc. by Juno Pharmaceuticals Corp., OraSure Technologies, Inc., Pfizer Inc., Premier Biotech, LLC, Psychemedics Corporation, Quest Diagnostics Incorporated, Sartorius AG, Securetec Detektions-Systeme AG, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., and United States Drug Testing Laboratories, Inc..
Market Segmentation & Coverage